4f mph
4F-MPH 30 MG Pellets (4-Fluoromethylphenidate) Price range: €18.95 through €549.95
Back to products
1cp-mipla
1cP-MiPLA 200 MCG Blotters Price range: €6.50 through €399.95
IDRA-21 10 MG Pellets - Image 1

IDRA-21 10 MG Pellets

IDRA-21 Pellets properties

Synonym: 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide
CAS Number: 22503-72-6
Formula: C8H9ClN2O2S
Molar mass: 232.6 g/mol
Purity: >97%

Price range: €13.50 through €398.58

Add to compare
Add to wishlist
SAVE 15%

more 2 products

SAVE 50%

6 for the price of 3

* The information on this page is a summary and is not intended to cover all available information about this medication. It does not cover all possible uses, directions, precautions, drug interactions or adverse effects and is not a substitute for the expertise and judgment of your healthcare professional.

IDRA-21 10 MG Pellets – Scientific Description & User Manual

Product Description

IDRA-21 (10 mg pellets) is a potential AMPA receptor potentiator which belongs to the class of nootropic and neuroprotective research chemicals. It works by enhancing glutamate-induced signaling in the brain, which may lead to improved cognitive function, neuroplasticity, and potentially neurorestoration.

These pellets are high purity (≥98%), standardized dosage and intended exclusively for scientific research and preclinical studies.

Uses & Applications

IDRA-21 is being studied for its possible effects on:

  1. Cognitive Enhancement – May increase alertness, learning ability and memory consolidation.

  2. Neuroprotection – Potential protective effect in neurodegenerative diseases (e.g. Alzheimer's, stroke).

  3. Neurological Recovery – May promote synaptic plasticity after brain injury.

  4. Scientific Research – Study of AMPA receptor modulation and glutamate signaling.

⚠ Not approved for human or veterinary use – For in vitro and controlled preclinical studies only.

Dosage & Safety Guidelines

  • Investigational dosage (in vitro/preclinical): 5–20 mg/kg (depending on model).

  • Pellet solution: Can be resolved in distilled water or DMSO for experiments.

  • Administration: Orally (animal models) or directly in cell cultures.

  • Frequency: Single dose for acute effect; long-term studies require careful monitoring.

🚨 NB:

  • No human application – No safety data for human use.

  • High doses may cause neuroexcitotoxicity.

  • Avoid combination with other glutamate modulators.

Disadvantages & Risks

  • Overstimulation of neurons (risk of excitotoxicity in case of overdose).

  • Possible anxiety or agitation in sensitive models.

  • Limited long-term data about tolerance and side effects.

  • Not suitable for chronic use without extensive toxicity studies.

Frequently Asked Questions (FAQ's)

1. Is IDRA-21 legal in the Netherlands?

Yes, but only for scientific researchIt does not fall under the Opium Act, but is also not approved as a medicine.

2. How exactly does IDRA-21 work?

It enhances AMPA receptor response, which makes glutamate signaling longer and more intense. This can lead to improved synaptic communication.

3. Does IDRA-21 compare to other nootropics?

It has a unique mechanism of action, but similar goals as racetams or ampakines (e.g. Sunifiram).

4. Are there any known interactions?

  • NMDA antagonists (e.g. Memantine) – Possible contradictory effects.

  • GABAergic substances (e.g. Benzodiazepines) – May reduce anxiolytic effects.

Lab Report & Quality Control

  • HPLC analysis: ≥98% purity.

  • No detectable heavy metals or solvent residues.

  • Homogeneous pellet formulation for consistent dosing.

  • Batch certification available for research institutions.

Recommended Research Scenarios

  1. Cognitive studies – Effects on memory and learning in animal models.

  2. Neuroprotective research – Potential role in ischemic damage (stroke models).

  3. Electrophysiology – AMPA receptor response measurements in neuronal cultures.

🔬 For controlled laboratory conditions only – No recreational use!